Therapeutic Goods Administration / TGA

Overview

The Therapeutic Goods Administration is Australia’s national regulator for therapeutic goods. The source presents it as the institution that makes supplement oversight look drug-like while leaving efficacy largely unsupervised.

Current Profile

According to the episode, Australia passed dedicated legislation in 1989 and gave the TGA responsibility for drugs and supplements together, similar in form to a combined food-and-drug authority, and every product sold, imported, or exported on the Australian market needs its own AUST number. The regulator sorts products into a listed and a registered track by efficacy claims and risk.

Most supplements are listed: they may use only TGA-permitted low-risk ingredients and low-level permitted claim language, the company applies for the number itself, and no pre-market review occurs - oversight is by post-market sampling. Prescription medicines, over-the-counter medicines, and a small number of higher-risk supplements are registered and require pre-market assessment of safety, quality, and efficacy; the source’s illustration is calcium, where ordinary strength can be listed while high-concentration calcium needs a registered number. The same source reports roughly 10,000 complementary medicines in Australia by around 2010 with close to 98% listed, and relays TGA guidance that consumers who take supplements should mention them when talking to hospital staff about their medication, because supplement ingredients act on the body.

Key Characteristics

• Regulates medicines and therapeutic supplements through one agency and one numbering system.
• Splits products into a self-assessed listed track and a pre-market-assessed registered track.
• Places the great majority of complementary medicines on the listed track.
• Controls permitted ingredients and claim wording rather than demonstrated benefit.
• Relies on post-market sampling instead of pre-market efficacy review for listed goods.
• Publishes consumer-facing warnings about supplement interactions and disclosure to clinicians.

Evidence

• Institutional design and numbering: Vol.275 澳洲保健品是怎么火起来的？ describes the 1989 legislation, combined drug-and-supplement remit, and mandatory AUST numbers.
• Listed versus registered tracks: Vol.275 澳洲保健品是怎么火起来的？ says most supplements are listed with permitted ingredients and low-level claims and no pre-market review, while higher-risk products are registered with safety, quality, and efficacy assessment.
• Risk-tiered example: Vol.275 澳洲保健品是怎么火起来的？ uses calcium strength to show how the same ingredient can sit on different tracks.
• Market composition: Vol.275 澳洲保健品是怎么火起来的？ reports about 10,000 complementary medicines by around 2010 with nearly 98% listed.
• Consumer disclosure guidance: Vol.275 澳洲保健品是怎么火起来的？ relays TGA advice that supplement use should be disclosed to hospital or medical staff.

Qualifications

The page records a podcast-level description of the regime rather than the legislation itself, so categories, thresholds, and the L/R examples should be checked against current TGA guidance before being relied on. Complementary-medicine counts and the 98% listed share are episode figures, and the source does not describe enforcement intensity, listing-compliance failures, or reform debates.

What Changed

• Created the TGA page as the regulator node for the Australian supplement branch.

Relationships

• Australian Therapeutic Goods Regulation / 澳洲保健品监管 - concept page covering the dual-track logic and its limits.
• Supplements Good Manufacturing Practice / 保健品GMP - manufacturing standard that the TGA framework relies on for process assurance.
• Supplement Structure Function Claims - claim-language boundary that the listed track enforces.
• Dietary Supplement Regulation - U.S. comparison where a different regulator and statute set weaker coverage.
• Post-Market Drug Surveillance - adjacent post-market supervision pattern.
• 斯维斯 and 澳佳宝 - listed supplement brands operating under this regime.
• Australia - jurisdiction the regulator governs.